FMC is in poor financial health. We calculate a net debt/adjusted EBITDA ratio of 4.3 times as of March 31. We expect FMC's leverage ratios will remain elevated over the next several years. However, ...

The industry has already demonstrated gains using AI in tight iteration loops, but how does that evolve to cover larger ...

Q1 2025 Earnings Call Transcript May 1, 2025 Operator: Good morning and welcome to the First Quarter 2025 Earnings Call for ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

BridgeBio's valuation relies on the commercialization of Attruby, but the drug's full potential may be undermined by tafamidis’ patent extension, introduction of generic alternatives, and other ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory ...

Q1 2025 Earnings Conference Call May 1, 2025 9:00 AM ETCompany ParticipantsCurt Brooks - Director of IRPierre Brondeau - ...

Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what ...

Fintech firm Kaleidofin raises $5.3 million from IDH Farmfit Fund, bringing its current equity round to $19 million to ...

Chennai-based Fintech firm Kaleidofin receives $5.3 million equity infusion from IDH Farmfit Fund, focusing on smallholder value chains.

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...